SCHEMBL8767247

SCHEMBL8767247

O=C(O)/C=C1\OC(=O)c2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
KDM4E B2RXH2 4/20 0.60
HPGD P15428 3/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
TDP1 Q9NUW8 2/20 0.60
LMNA P02545 1/20 0.54
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
ALOX15 P16050 1/20 0.52
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
TRPA1 O75762 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17293790 1.00 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDL3MBTL1TDP1
SCHEMBL8767253 1.00 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDL3MBTL1TDP1
SCHEMBL10717055 0.82 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDL3MBTL1TDP1
SCHEMBL23909069 0.81 CCNB2 (0.42) ALDH1A1KDM4EHPGDL3MBTL1TDP1
SCHEMBL18265864 0.80 KDM4E (0.43) ALDH1A1KDM4EHPGDL3MBTL1TDP1
SCHEMBL19575376 0.80 KDM4E (0.43) ALDH1A1KDM4EHPGDL3MBTL1TDP1
Phthalic Anhydride SCHEMBL27856846 0.78 TDP1 (0.64) ALDH1A1KDM4EHPGDL3MBTL1TDP1
SCHEMBL15473352 0.78 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDL3MBTL1TDP1
SCHEMBL11215773 0.78 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDL3MBTL1TDP1
SCHEMBL11215775 0.78 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2009867-A None JP disclosed
EP-3649119-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2021-11-03 EP disclosed
EP-3649119-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2021-11-03 EP disclosed
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GILEAD SCIENCES, INC. 2021-10-14 US disclosed
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GILEAD SCIENCES, INC. 2021-10-14 US disclosed
US-7314879-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2008-01-01 US disclosed
US-7314879-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2008-01-01 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7186715-B2 Piperazine- and piperidine-derivatives as melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-03-06 US disclosed
EP-0652213-B1 Method for producing alkyl 3-phthalidylideneacetate SUMIKA FINE CHEMICALS CO LTD (JP) 1997-08-27 EP disclosed
US-5508446-A Method for producing alkyl 3-phthalidylideneacetate SUMIKA FINE CHEMICALS CO., LTD. (JP) 1996-04-16 US disclosed
EP-0652213-A1 Method for producing alkyl 3-phthalidylideneacetate SUMIKA FINE CHEMICALS Co., Ltd. (JP) 1995-05-10 EP disclosed
EP-0331314-B1 Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate PFIZER (US) 1994-04-06 EP disclosed
US-4940791-A Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate PFIZER INC. (US) 1990-07-10 US disclosed
US-4940791-A Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate PFIZER INC. (US) 1990-07-10 US disclosed
US-4904782-A Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate PFIZER INC. (US) 1990-02-27 US disclosed
US-4904782-A Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate PFIZER INC. (US) 1990-02-27 US disclosed
JP-H029867-A PRODUCTION OF PHTHALAZINEACETIC ACID ESTER DERIVATIVE AND NOVEL INTERMEDIATE PFIZER INC 1990-01-12 JP disclosed
EP-0331314-A2 Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate PFIZER INC. (US) 1989-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS S1PR1, S1PR3, S1PR2 ALDH1A1 944/4885KDM4E 3835/4885HPGD 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.